Dyslipidemia characterized by high plasma triglycerides and low HDL-cholesterol is a key risk factor for cardiovascular disease. There are approximately 150 million people with this type of dyslipidemia in the G7 countries and 60 million of them are considered as high-risk patients. Lipigon Pharmaceuticals develops innovative first-in-class drugs aiming at treating these patients.
- Bli medlem
- Om SwedenBIO